“…New approach methodologies (NAMs), which include in silico , in chemico , in vitro , and ex vivo approaches [47] , [48] , are being rapidly developed because of, while not yet fully validated their potential to reliably reflect human biology [49] . Recently, the 3D bronchial epithelial model has been applied as mechanistic follow-up in vitro toxicity comparison among CS and THS2.2 [50] , THP1.0 [51] , [52] , or the other type of HTP [31] , [53] , [54] . These assessments using NAMs such as human 3D tissue models, once fully validated, would also contribute to the examination of reduced risk potential of DT3.0a.…”